Page 356 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
Kagawa Medical 50-80 yr, initial PSA every 2 mo for 6 mo, every 3 mo thereafter. PSADT ≤2 yr after 6 mo NR
Univ., Japan 118 PSA ≤20 Re-biopsy at 1 yr (no data beyond 1 yr) (based on all PSA or most
[18272471] ng/mL, 1-2 recent 1 yr)
positive cores Re-biopsy did not fit initial
2002-2003 per 6-12 pathology criteria
systematic
biopsy cores,
Gleason score
≤6, ≤50%
cancer
involvement in
any core.
Excluded if
comorbidities:
past stroke,
unstable
angina, DM
uncontrollable
with insulin,
severe HTN, MI
w/in 6 mo.
Kansas City VA, Low-risk prostate PSA every 3 mo and a repeat TRUS guided prostate biopsy at 1 NR NR
US 158 cancer patients: yr. All biopsies were performed using a standard 12-core
[21172105]] stage T2 or biopsy scheme, however, an increased number of biopsies
less, Gleason were taken for larger glands.
2004-2009 ≤6, PSA <20
ng/mL, and
percent of total
tissue on biopsy
positive for
cancer <20%

C-96